New blood test could spot hidden tumors in rare genetic disease
NCT ID NCT06430021
First seen Mar 28, 2026 · Last updated May 15, 2026 · Updated 11 times
Summary
This study is testing whether a new blood test that measures a protein called hPG80 can help detect neuroendocrine tumors (NETs) earlier in people with MEN1, a rare genetic condition that raises the risk for these tumors. About 297 participants with MEN1 will give blood samples, and results will be compared with standard imaging scans. If successful, this test could offer a simpler, less stressful way to monitor for tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chu Dijon Bourgogne
RECRUITINGDijon, 21000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.